Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Data ReadoutpositivePositive

AI Analysis

Summary

Disc Medicine presented updated positive data from its RALLY-MF Phase 2 trial in myelofibrosis patients with anemia at the 2026 ASCO Annual Meeting. The data presentation represents progress in the company's clinical development program for this indication.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Updated positive data from RALLY-MF Phase 2 trial presented at ASCO Annual Meeting

Importance:6/10

Sentiment:

0.70

Phase 2 dataMyelofibrosisASCO 2026Positive resultsRALLY-MF trial

Related Companies

$IRON

Read the original article

Published by yahoo_finance on June 2, 2026 12:00 PM

Read Original